Page 41 - Nsclc News Today

Focused discussion on the selection of neoadjuvant therapy in patients with resectable NSCLC in light of recent clinical trials.

Expert oncologists reflect on key factors that aid in the selection of therapy for patients diagnosed with resectable non–small cell lung cancer (NSCLC).

Mark A. Socinski, MD, executive director of thoracic cancer at AdventHealth Cancer Institute, discusses the importance of biomarker testing in non–small cell lung cancer (NSCLC).

New guidance on the use of definitive local therapy to treat patients with oligometastatic non–small cell lung cancer has been issued by the American Society for Radiation Oncology and European Society for Radiotherapy and Oncology.

The American Society for Radiation Oncology (ASTRO) and European Society for Radiotherapy and Oncology (ESTRO) jointly released a clinical guideline on the use of definitive local therapy for the treatment of oligometastatic non–small cell lung cancer (NSCLC).

The panel discusses how patients with advanced NSCLC are sub-grouped in NSCLC and how to approach treatment for each group.

Marina Garassino, MD, reviews the role of PD-L1 testing in advanced non-small cell lung cancer.

Jason J. Luke, MD, FACP, discusses initial results from the phase 1 GLIMMER-01 trial of E-602 in advanced solid tumors.

The AEGEAN trial is the second phase 3 study, after Checkmate 816, to demonstrate a benefit from neoadjuvant immunotherapy for patients with resectable non–small cell lung cancer.

Perioperative toripalimab plus chemotherapy significantly improved EFS and reduced risk of disease recurrence, progression events or death by 60% among resectable stage III NSCLC patients, compared to